# Phase III study evaluating the efficacy of Drogenil in pancreatic carcinoma

Submission date Recruitment status Prospectively registered 19/08/2002 No longer recruiting [ ] Protocol [ ] Statistical analysis plan Registration date Overall study status 19/08/2002 Completed [X] Results Individual participant data **Last Edited** Condition category 30/10/2019 Cancer

#### Plain English summary of protocol

Not provided at time of registration

#### Contact information

#### Type(s)

Scientific

#### Contact name

Dr--

#### Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

#### Additional identifiers

**Protocol serial number** NHS 1

# Study information

#### Scientific Title

Phase III study evaluating the efficacy of Drogenil in pancreatic carcinoma

#### **Study objectives**

Not provided at time of registration

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

#### Study type(s)

Treatment

#### Health condition(s) or problem(s) studied

Carcinoma of the pancreas

#### **Interventions**

- 1. Group A: Flutamide 250 mg three times daily
- 2. Group B: Placebo

#### Intervention Type

Drug

#### **Phase**

Phase III

### Drug/device/biological/vaccine name(s)

Drogenil (flutamide)

#### Primary outcome(s)

Not provided at time of registration

#### Key secondary outcome(s))

Not provided at time of registration

#### Completion date

31/01/1997

# Eligibility

#### Key inclusion criteria

Not provided at time of registration

#### Participant type(s)

Patient

#### Healthy volunteers allowed

No

#### Age group

**Not Specified** 

#### Sex

**Not Specified** 

#### Key exclusion criteria

Not provided at time of registration

#### Date of first enrolment

01/01/1995

#### Date of final enrolment

31/01/1997

## Locations

#### Countries of recruitment

**United Kingdom** 

England

# Study participating centre MRC Clinical Trials Unit

London United Kingdom NW1 2DA

# Sponsor information

#### Organisation

Schering-Plough Ltd (UK)

#### **ROR**

https://ror.org/00148fb49

# Funder(s)

#### Funder type

Industry

#### Funder Name

Schering-Plough Ltd (UK)

# **Results and Publications**

Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

#### **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	presumed results	27/06/1998	30/10/2019	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes